Total Company Value: cbdMD, Inc. (YCBD)

cbdmd.com - graphic logo of issuer YCBD

The share price of cbdMD, Inc. (YCBD), which currently stands at 4.24 as shown in the chart below, relates to the CBD product manufacturing business. The firm's success relies on customer loyalty and retail availability. High quality and brand recognition hinder the expansion of smaller players, despite stringent FDA oversight. Currently, cbdMD, Inc. (YCBD) is combating market stagnation through cost reduction and catalog updates.

YCBD (cbdMD Inc.) Total Company Value history from 11/23/2025 to 10/28/2026
Original product of cbdMD

Investors are assessing the potential of cbdMD, Inc. (YCBD) by analyzing the enterprise value, which aggregates market capitalization and liabilities minus liquid assets. By analyzing the indicative enterprise value level, one can determine the actual acquisition price of the company, taking into account its success in retail sales of legal CBD products for humans and animals. This provides an understanding of whether the market is overpaying for the brand's current leadership.

Competitor analysis for cbdMD, Inc.

Real Price to Acquire Entire Company Haleon PLC HLN|KVUE - Enterprise Value|VRNA - Total Company Value|Enterprise Value Jyong Biotech Ltd|LGND (ligand.com) - Business Value|Total Company Value Amneal AMRX|Full Business Value Perrigo Company PLC|Alvotech Corp (ALVO) - Enterprise Value|Value Adjusted for Debt and Cash Liquidia Inc. (LQDA)|Enterprise Value GLPG (Galapagos NV)|anipharmaceuticals.com - Enterprise Value|Total Company Value MannKind (MNKD)|AMPH: Value Adjusted for Debt and Cash|PCRX (Pacira) - Total Company Value|ARS Corp (SPRY) - Real Price to Acquire Entire Company|TBPH (Theravance Biopharma) - Enterprise Value|Enterprise Value aquestive.com (AQST)|scPharmaceuticals Inc. (SCPH) - Real Price to Acquire Entire Company|Value Adjusted for Debt and Cash TECX (tectonictx.com)|TNXP: Total Company Value|SXTC - Total Enterprise Value|Real Price to Acquire Entire Company Eupraxia Pharma EPRX|BHST - Aggregate Business Value|Enterprise Value eXoZymes EXOZ|Oramed Pharmaceuticals Inc. (ORMP) - Value Adjusted for Debt and Cash|Enterprise Value ENTX (Entera Bio Ltd)|Total Enterprise Value HYFT|ABVC BioPharma (ABVC) - Total Company Value|Value Adjusted for Debt and Cash cumberlandpharma.com (CPIX)|Quantum BioPharma - Enterprise Value|Real Price to Acquire Entire Company FibroGen Inc FGEN|TELO - Enterprise Value|RANI - Total Company Value|Enterprise Value synergychc.com|RLYB (Rallybio) - Business Value|Total Company Value LEXX|Real Price to Acquire Entire Company Pulmatrix Inc|Enterprise Value Pheton Holdings Ltd PTHL|Business Value aptorumgroup.com APM|Real Price to Acquire Entire Company Lyra Therapeutics, Inc.|Value Adjusted for Debt and Cash Impact BioMedical, Inc. IBO|Enterprise Value TNFA (TNF Pharma)|PRFX: Company Buyout Price|Total Company Value altamiratherapeutics.com|Lipella Pharma (LIPO) - Business Value|Enterprise Value OPTN|Real Price to Acquire Entire Company pieris.com (PIRS)|PROC (Procaps) - Real Price to Acquire Entire Company|Company Buyout Price Petros Pharmaceuticals Inc PTPI|QLI: Real Price to Acquire Entire Company|Total Enterprise Value ACELYRIN Inc. SLRN|TFFP: Enterprise Value